Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Abstract

Objectives: This study aims to compare the effectiveness of desloratadine monotherapy and desloratadine plus montelukast combination therapy on quality of life in patients with persistent allergic rhinitis. Patients and Methods:This study consists of 40 patients (28 females, 12 males, mean age 29.8 years; range 17 to 44 years) referred to ear, nose, and throat outpatient clinic between May 2010 and September 2010. A six-week randomized, doubleblind, cross-sectional study was performed in two arms: In group 1, 20 patients received desloratadine (5 mg/d) alone; in group 2, 20 patients received desloratadine (5 mg) plus montelukast (10 mg) combination therapy. Quality of life was assessed on the day before starting treatment and on the last day of each treatment period using the Rhinoconjunctivitis Quality of Life Questionnaire and Nighttime Symptom Scores. Results:In group 1, the mean quality of life scores before and after treatment were 3.17 and 2.43, respectively. In group 2, the mean quality of life scores before and after treatment were 2.94 and 1.73, respectively. Conclusion:Desloratadine plus montelukast combination therapy may have a positive impact on quality of life, sleep symptoms in particular.Keywords: Desloratadine; montelukast; persistent allergic rhinitis; quality of life.Amaç: Bu çalışmada inatçı alerjik rinit hastalarında desloratadin monoterapisi ve desloratadin artı montelukast kombinasyon tedavisinin yaşam kalitesi üzerine etkinliği karşılaştırıldı. Bulgular: Grup 1'de tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 3.17 ve 2.43 idi. Grup 2'de ise, tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 2.94 ve 1.73 idi.Sonuç: Desloratadin artı montelukast kombinasyon tedavisinin, özellikle uyku semptomları olmak üzere, yaşam kalitesi üzerine olumlu bir etkisi olabilir.Anahtar Sözcükler: Desloratadin; montelukast; inatçı allerjik rinit; yaşam kalitesi.

Leukotriene Receptor Antagonist Addition to H1-Antihistamine Is Effective for Treating Allergic Rhinitis: A Systematic Review and Meta-analysis

“…11,[13][14][15] At the end, 14 studies (15 articles) were included. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Characteristics of the included studies are shown in Table 1. A flow chart of the study retrieval and selection is presented in Figure 1.…”

“…Eight RCTs studied patients with seasonal AR (SAR) 12,16,19,21,22,24,25 and 6 RCTs studied perennial AR (PAR). 11,17,18,20,23 Four RCTs studied patients with persistent AR. 11,17,20 Two trials included patients with AR and comorbid asthma.…”

“…11,17,18,20,23 Four RCTs studied patients with persistent AR. 11,17,20 Two trials included patients with AR and comorbid asthma. 12,20 Patients with asthma were excluded from 11 trials.…”

“…12,20 Patients with asthma were excluded from 11 trials. 11,[16][17][18][19][21][22][23][24][25] Intervention All RCTs used second-generation oral AHs as AHs and montelukast as LTRA. One trial used 2 different kinds of AHs on each arm of the study: fexofenadine for the AH arm and loratadine with LTRA for the AH-LTRA arm.…”

An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel

“…For patients who do not tolerate INCSs or prefer not to use them, adding a leukotriene receptor antagonist to an oral or topical AH may be considered. 42,43 Responsive patients should be instructed to continue therapy during periods of allergen exposure. Those non-responsive to therapy (e.g., symptomatic after 4 weeks) should be stepped up.…”